Medtronic plc (NYSE:MDT) traded at $128.69 at last check on Tuesday, May 04, made a downturn move of -1.91% on its previous day’s price.
Looking at the stock we see that its previous close was $131.2 and the beta (5Y monthly) reads 0.8 with the day’s price range being $128.50 – 131.35. The company has a trailing 12-month PE ratio of 62.09. In terms of its 52-week price range, MDT has a high of $132.3 and a low of $87.68. The company’s stock has gained about 11.01% over that past 30 days.
Medtronic plc has a market cap of $177.65 Billion and is expected to release its quarterly earnings report on May 27, 2021. With its Forward Dividend at 2.32 and a yield of 1.77%, the company’s investors could be anxious for the MDT stock to gain ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $1.42, with the EPS growth for the year declined at $4.34 for 2021 and $5.72 for next year. These figures represent -0.05% and 0.32% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $8.14 Billion, with a low of $7.99 Billion and a high of $8.44 Billion. The median projection represents growth adding up to 35.8% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $29.98 Billion, or +3.7% up from figures reported last year.
On the other hand, looking at the outlook for the MDT stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 27 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 5 have rated the Medtronic plc (MDT) stock as a Hold, while 19 rate it as a Buy. 3 analyst(s) rate it as outperform while none of them rated it as underperform, whereas none suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the MDT stock currently stands at 6.84, and the most recent price level today is 1.49% off its SMA20 and 6.01% from its 50-day simple moving average. The RSI (14) is pointing at 60.07 while the volatility over the past week is 1.07% and jumps to 1.39% over the past one month. The beta value is 0.8, while the average true range (ATR) is currently pointing at 1.76. The average price target for the stock over the next 12 months is $135.21, with the estimates having a low of $124 and a high of $153. These price ends are -3.64% and +18.89% off the today’s price level respectively, although investors could be excited at the prospect of a +4.9% if the MDT share price touches on the median price of $135.
Let’s briefly compare Medtronic plc (MDT) stock to its peers. We find that today’s price change of -1.91% and +37.9% over the past 12 months for MDT betters that of Abbott Laboratories (ABT), which has seen its stock price fall -1.95% in the latest trading session and is +33.03% over the last one year. Another of its peers Stryker Corp (SYK) has dropped -3.12% today, and was +45.66% up over the past year, while Boston Scientific Corp (BSX) is also down -1.91% yet, while its price remains in the green at 37.9% over the same period. Medtronic plc has a P/E ratio of 62.09 compared to Abbott Laboratories’ 37.24 and Stryker Corp’s 71.22. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -1.21% and -0.62%, respectively, in early deals.
Coming back to Medtronic plc (NYSE:MDT), we note that the average 3-month trading volume was 4.71 Million, while that of the preceding 10-day period stands at 5.13 Million. Current shares outstanding are 1.35 Billion.
According to data from Thomson Reuters, insiders hold 0.07% of the company’s shares while institutions hold 83.28%. The data shows that short shares as of April 14, 2021, stood at 11.66 Million at a short ratio of 2.32. This represents a 0.87% short interest in shares outstanding on April 14, 2021. Shares short rose in April from the previous month at 7.51 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +12% up in year-to-date price movement.